Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
bevacizumab (avastin) (1 trial)
carboplatin (paraplatin) (1 trial)
durvalumab (imfinzi) (1 trial)
gemcitabine (gemzar) (1 trial)
hs-130 (1 trial)
viagenpumatucel-l (1 trial)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Lung Neoplasms (Phase 2)
Neoplasms (Phase 1)
Trials (3 total)
Trial APIs (6 total)